Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss current standards for unresectable, nonmetastatic hepatocellular carcinoma.
Back
Exploring Immunotherapy Approaches in Unresectable, Nonmetastatic Hepatocellular Carcinoma
Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, highlight ongoing research in unresectable, nonmetastatic HCC.
Exploring Immunotherapy Approaches in Unresectable, Nonmetastatic Hepatocellular Carcinoma
Episodes
All
All
Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss data for lenvatinib, pembrolizumab, and TACE from LEAP-012 in HCC.
Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss implications of China’s approval of lenvatinib, pembrolizumab, and TACE for unreseactable, nonmetastatic HCC.
Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss the use of systemic therapy to achieve downstaging in unreeseactable, nonmetastatic HCC.
Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss novel treatment approaches being explored in unreseactable, nonmetastatic HCC.
Stephen Lam Chan, MBBS, MD, FRCP, FHKCP, FHKAM, and Gonzalo Cantis, MD, discuss ongoing trials in unreseactable, nonmetastatic HCC.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Daraxonrasib in Previously Treated Metastatic Pancreatic Cancer
2
Dr Akhade on Building the Evidence Base for Low-Dose Immunotherapy
3
Epcoritamab Misses Sole US Primary End Point of Overall Survival in R/R DLBCL
4
Teclistamab Plus Talquetamab Yields Significant Survival Benefits in Earlier-Line R/R Myeloma
5